Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ALAD | P13716 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 2/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987523 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL988896 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL12531530 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL29061720 | 0.77 | CYP11B1 (0.44) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL9052922 | 0.76 | CYP2A6 (0.42) | CYP11B1CYP11B2CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL2600215 | 0.76 | ALDH1A1 (0.50) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL10955360 | 0.76 | PTGS2 (0.42) | ALDH1A1NPC1RAB9AMAPK1MMP12 | |
| SCHEMBL5147277 | 0.75 | CYP11B1 (0.45) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL2600064 | 0.75 | CYP11B1 (0.45) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 | |
| SCHEMBL14468248 | 0.75 | CYP11B1 (0.45) | CYP11B1CYP11B2HDAC6ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | disclosed |
| US-6426354-B1 | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; BRAIN DISORDERS | NOVARTIS AG (CH) | 2002-07-30 | — | — | US | disclosed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
| EP-0032432-B1 | PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 1985-07-24 | — | — | EP | disclosed |
| US-4438111-A | PROSTAGLANDINS, ANTICOAGULANTS, ANTIASTHMA | GLAXO GROUP LIMITED (GB) | 1984-03-20 | — | — | US | disclosed |
| US-4327092-A | USEFUL AS ANTICOAGULANTS AND ANTI-HISTAMINES | GLAXO GROUP LIMITED (GB) | 1982-04-27 | — | — | US | disclosed |
| EP-0032432-A1 | Prostanoid compounds and their preparation and pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 1981-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | CYP11B1 22/4885CYP11B2 20/4885HDAC6 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.